Dannheim Friederike M, Walsh Stephen J, Orozco Carolina T, Hansen Anders Højgaard, Bargh Jonathan D, Jackson Sophie E, Bond Nicholas J, Parker Jeremy S, Carroll Jason S, Spring David R
Yusuf Hamied Department of Chemistry, University of Cambridge Cambridge CB2 1EW UK
Cancer Research UK Cambridge Institute, University of Cambridge Cambridge CB2 0RE UK
Chem Sci. 2022 Jul 20;13(30):8781-8790. doi: 10.1039/d2sc02198f. eCollection 2022 Aug 4.
Antibody-drug conjugates (ADCs) are valuable therapeutic entities which leverage the specificity of antibodies to selectively deliver cytotoxins to antigen-expressing targets such as cancer cells. However, current methods for their construction still suffer from a number of shortcomings. For instance, using a single modification technology to modulate the drug-to-antibody ratio (DAR) in integer increments while maintaining homogeneity and stability remains exceptionally challenging. Herein, we report a novel method for the generation of antibody conjugates with modular cargo loading from native antibodies. Our approach relies on a new class of disulfide rebridging linkers, which can react with eight cysteine residues, thereby effecting all-in-one bridging of all four interchain disulfides in an IgG1 antibody with a single linker molecule. Modification of the antibody with the linker in a 1 : 1 ratio enabled the modulation of cargo loading in a quick and selective manner through derivatization of the linker with varying numbers of payload attachment handles to allow for attachment of either 1, 2, 3 or 4 payloads (fluorescent dyes or cytotoxins). Assessment of the biological activity of these conjugates demonstrated their exceptional stability in human plasma and utility for cell-selective cytotoxin delivery or imaging/diagnostic applications.
抗体药物偶联物(ADCs)是有价值的治疗实体,它利用抗体的特异性将细胞毒素选择性地递送至表达抗原的靶标,如癌细胞。然而,目前其构建方法仍存在许多缺点。例如,使用单一修饰技术以整数增量调节药物与抗体比率(DAR),同时保持均一性和稳定性仍然极具挑战性。在此,我们报告了一种从天然抗体生成具有模块化载药量的抗体偶联物的新方法。我们的方法依赖于一类新型的二硫键重桥连接头,其可与八个半胱氨酸残基反应,从而用单个接头分子实现IgG1抗体中所有四个链间二硫键的一体化桥连。以1:1的比例用接头修饰抗体,通过用不同数量的有效载荷连接柄对接头进行衍生化,从而能够快速且选择性地调节载药量,以允许连接1、2、3或4个有效载荷(荧光染料或细胞毒素)。对这些偶联物的生物学活性评估表明,它们在人血浆中具有出色的稳定性,可用于细胞选择性细胞毒素递送或成像/诊断应用。